

17-03-2026 h 18.00-19.00

Faculty

Marzia Del Re, Patrizia Giannatempo, Sara Scagliarini, Brigida Maiorano, Chiara Mercinelli

Program

The webinar will discuss emerging practice-changing data related to the use of liquid biopsy in genito-urinary cancers presented at the 2026 ASCO GU.

Topics:

- ctDNA for MRD assessment
- ctDNA dynamics to monitor treatment response
- ctDNA to identify predictive biomarkers of response/resistance to approved and emerging treatment strategies

Key 2026 ASCO GU Liquid Biopsy Focus Areas & Emerging Data che verranno discussi durante il webinar:

Bladder Cancer (Muscle-Invasive): Ongoing trials are evaluating liquid biopsy (ctDNA) to detect molecular residual disease (MRD) post-surgery to guide adjuvant therapy decisions.

Prostate Cancer: Studies are highlighting the use of ctDNA to track resistance mechanisms and inform treatment strategies, including in metastatic castration-resistant prostate cancer (mCRPC).

Actionable Biomarkers: Liquid biopsy is increasingly used to identify predictive biomarkers (e.g., FGFR alterations, HER2) in circulating DNA to guide therapy selection.

Combination Therapies: Research presented includes, for example, the use of liquid biopsy to guide treatment with disitamab vedotin.

Targeted Agents: Data is featured on specific inhibitors, such as the PPAR- γ inhibitor FX-909 in urothelial cancer, which may be refined using biomarker-defined populations.

Note: The 2026 ASCO GU Symposium takes place from February 26-28, 2026, and specific trial results, particularly late-breaking abstracts, will be finalized closer to or during the event.